Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:KRYS NASDAQ:PTCT NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$4.48+3.0%$3.90$3.21▼$7.18$1.07B0.64.40 million shs6.18 million shsKRYSKrystal Biotech$143.34+2.6%$137.47$122.80▼$219.34$4.14B0.67287,072 shs246,977 shsPTCTPTC Therapeutics$47.65-0.7%$48.17$29.02▼$58.38$3.78B0.5865,435 shs1.21 million shsSRPTSarepta Therapeutics$19.03+9.9%$34.46$16.88▼$154.90$1.87B0.452.22 million shs5.80 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+1.28%+10.97%+18.21%+0.46%-17.77%KRYSKrystal Biotech-2.29%+1.66%+2.04%-11.94%-24.19%PTCTPTC Therapeutics-1.62%-1.76%-7.96%+20.64%+55.12%SRPTSarepta Therapeutics-4.91%+1.29%-59.73%-64.87%-88.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.4392 of 5 stars3.53.00.04.42.52.50.6KRYSKrystal Biotech4.491 of 5 stars3.51.00.04.72.22.51.9PTCTPTC Therapeutics4.2996 of 5 stars4.31.00.04.41.50.81.3SRPTSarepta Therapeutics4.73 of 5 stars4.22.00.04.22.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89143.06% UpsideKRYSKrystal Biotech 3.00Buy$211.1347.29% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0036.41% UpsideSRPTSarepta Therapeutics 2.44Hold$60.88219.89% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, KRYS, SRPT, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell6/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M3.21N/AN/A$0.73 per share6.14KRYSKrystal Biotech$290.52M14.26$4.65 per share30.85$32.90 per share4.36PTCTPTC Therapeutics$806.78M4.68N/AN/A($14.24) per share-3.35SRPTSarepta Therapeutics$2.23B0.84$2.54 per share7.49$15.99 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A14.45N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1634.4614.22N/A37.17%14.64%13.28%8/4/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.32N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.74N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest ARDX, KRYS, SRPT, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81KRYSKrystal BiotechN/A9.659.27PTCTPTC TherapeuticsN/A3.893.85SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%KRYSKrystal Biotech86.29%PTCTPTC TherapeuticsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%KRYSKrystal Biotech13.70%PTCTPTC Therapeutics5.50%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableARDX, KRYS, SRPT, and PTCT HeadlinesRecent News About These CompaniesClass Action Announcement for Sarepta Therapeutics, Inc. (SRPT): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc.3 hours ago | prnewswire.comSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT3 hours ago | globenewswire.comSarepta Therapeutics (NASDAQ:SRPT) Trading 7.2% Higher - Should You Buy?July 8 at 12:38 PM | marketbeat.comSRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLPJuly 8 at 10:02 AM | prnewswire.comLevi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPTJuly 8 at 9:00 AM | prnewswire.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud LawsuitJuly 7 at 8:12 PM | prnewswire.comNASDAQ: SRPT: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc.July 7 at 7:03 PM | businesswire.comSRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitJuly 7 at 5:40 PM | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPTJuly 7 at 5:35 PM | globenewswire.comRobbins LLP Reminds Sarepta Therapeutics, Inc. Investors with Large Losses to Contact the Firm for Information About the SRPT Class Action LawsuitJuly 7 at 5:24 PM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Lawsuit – SRPTJuly 7 at 4:40 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPTJuly 7 at 2:45 PM | prnewswire.comSAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming DeadlineJuly 7 at 11:42 AM | globenewswire.comAugust 25, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SRPTJuly 7 at 9:00 AM | prnewswire.comINVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, ...July 7 at 5:24 AM | gurufocus.comINVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)July 7 at 4:04 AM | prnewswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Allspring Global Investments Holdings LLCJuly 7 at 3:42 AM | marketbeat.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 6 at 8:15 AM | globenewswire.comINVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, ...July 5 at 6:27 PM | gurufocus.comROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 5 at 2:31 PM | markets.businessinsider.comINVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 5 at 11:40 AM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, KRYS, SRPT, and PTCT Company DescriptionsArdelyx NASDAQ:ARDX$4.48 +0.13 (+2.99%) Closing price 04:00 PM EasternExtended Trading$4.51 +0.03 (+0.78%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Krystal Biotech NASDAQ:KRYS$143.34 +3.60 (+2.58%) Closing price 04:00 PM EasternExtended Trading$144.50 +1.16 (+0.81%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$47.65 -0.33 (-0.69%) Closing price 04:00 PM EasternExtended Trading$48.15 +0.50 (+1.05%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Sarepta Therapeutics NASDAQ:SRPT$19.03 +1.71 (+9.87%) Closing price 04:00 PM EasternExtended Trading$19.04 +0.01 (+0.05%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
